part, addressed in this clinical protocol. Because there are possible added side 
effects resulting from the increased production of TNF by TIL the. clinical protocol 
involves the use of increasing the numbers of cells starting at a very low cell 
number that is not expected to cause side effects. If levels of the transferred 
cells given to patients do cause side effects then no higher doses will be given. 
The gene modified TIL will be administered along with another substance called 
interleuk.in-2 which helps keep these cells alive in the body. 
Extensive studies will be performed in patients to monitor the survival of 
the TIL in the patient as well as to determine any possible side effects or 
therapeutic benefit that result from this treatment. 
Recombinant DNA Research, Volume 14 
[307] 
